Chalcone-1-Deoxynojirimycin Heterozygote Reduced the Blood Glucose Concentration and Alleviated the Adverse Symptoms and Intestinal Flora Disorder of Diabetes Mellitus Rats
Chalcone-1-deoxynojirimycin heterozygote (DC-5), a novel compound which was designed and synthesized in our laboratory for diabetes treatment, showed an extremely strong in vitro inhibitory activity on α-glucosidase in our previous studies. In the current research, its potential in vivo anti-diabetic effects were further investigated by integration detection and the analysis of blood glucose concentration, blood biochemical parameters, tissue section and gut microbiota of the diabetic rats. The results indicated that oral administration of DC-5 significantly reduced the fasting blood glucose and postprandial blood glucose, both in diabetic and normal rats; meanwhile, it alleviated the adverse symptoms of elevated blood lipid level and lipid metabolism disorder in diabetic rats. Furthermore, DC-5 effectively decreased the organ coefficient and alleviated the pathological changes of the liver, kidney and small intestine of the diabetic rats at the same time. Moreover, the results of 16S rDNA gene sequencing analysis suggested that DC-5 significantly increased the ratio of Firmicutes to Bacteroidetes and improved the disorder of gut microbiota in diabetic rats. In conclusion, DC-5 displayed a good therapeutic effect on the diabetic rats, and therefore had a good application prospect in hypoglycemic drugs and foods.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Molecules (Basel, Switzerland) - 27(2022), 21 vom: 04. Nov. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Xiao, Pin-Jian [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 14.11.2022 Date Revised 17.11.2022 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/molecules27217583 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM34877995X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM34877995X | ||
| 003 | DE-627 | ||
| 005 | 20231226041049.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/molecules27217583 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1162.xml |
| 035 | |a (DE-627)NLM34877995X | ||
| 035 | |a (NLM)36364410 | ||
| 035 | |a (PII)7583 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Xiao, Pin-Jian |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Chalcone-1-Deoxynojirimycin Heterozygote Reduced the Blood Glucose Concentration and Alleviated the Adverse Symptoms and Intestinal Flora Disorder of Diabetes Mellitus Rats |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.11.2022 | ||
| 500 | |a Date Revised 17.11.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Chalcone-1-deoxynojirimycin heterozygote (DC-5), a novel compound which was designed and synthesized in our laboratory for diabetes treatment, showed an extremely strong in vitro inhibitory activity on α-glucosidase in our previous studies. In the current research, its potential in vivo anti-diabetic effects were further investigated by integration detection and the analysis of blood glucose concentration, blood biochemical parameters, tissue section and gut microbiota of the diabetic rats. The results indicated that oral administration of DC-5 significantly reduced the fasting blood glucose and postprandial blood glucose, both in diabetic and normal rats; meanwhile, it alleviated the adverse symptoms of elevated blood lipid level and lipid metabolism disorder in diabetic rats. Furthermore, DC-5 effectively decreased the organ coefficient and alleviated the pathological changes of the liver, kidney and small intestine of the diabetic rats at the same time. Moreover, the results of 16S rDNA gene sequencing analysis suggested that DC-5 significantly increased the ratio of Firmicutes to Bacteroidetes and improved the disorder of gut microbiota in diabetic rats. In conclusion, DC-5 displayed a good therapeutic effect on the diabetic rats, and therefore had a good application prospect in hypoglycemic drugs and foods | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a blood biochemical analysis | |
| 650 | 4 | |a chalcone 1-deoxynojirimycin heterozygote | |
| 650 | 4 | |a gut microbiota | |
| 650 | 4 | |a postprandial blood glucose | |
| 650 | 7 | |a Blood Glucose |2 NLM | |
| 650 | 7 | |a 1-Deoxynojirimycin |2 NLM | |
| 650 | 7 | |a 19130-96-2 |2 NLM | |
| 650 | 7 | |a Chalcones |2 NLM | |
| 650 | 7 | |a Chalcone |2 NLM | |
| 650 | 7 | |a 5S5A2Q39HX |2 NLM | |
| 650 | 7 | |a Hypoglycemic Agents |2 NLM | |
| 700 | 1 | |a Zeng, Jia-Cheng |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Ping |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Dao-Bang |e verfasserin |4 aut | |
| 700 | 1 | |a Yuan, En |e verfasserin |4 aut | |
| 700 | 1 | |a Tu, Yong-Gang |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Qing-Feng |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Ji-Guang |e verfasserin |4 aut | |
| 700 | 1 | |a Peng, Da-Yong |e verfasserin |4 aut | |
| 700 | 1 | |a Yin, Zhong-Ping |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecules (Basel, Switzerland) |d 2004 |g 27(2022), 21 vom: 04. Nov. |w (DE-627)NLM172073448 |x 1420-3049 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2022 |g number:21 |g day:04 |g month:11 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/molecules27217583 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2022 |e 21 |b 04 |c 11 | ||